Literature DB >> 19497077

Factors influencing adherence to referral advice following pre-referral treatment with artesunate suppositories in children in rural Tanzania.

Daudi O Simba1, Marian Warsame, Omari Kimbute, Deodatus Kakoko, Max Petzold, Goran Tomson, Zul Premji, Melba Gomes.   

Abstract

OBJECTIVE: WHO recommends artemisinin suppository formulations as pre-referral treatment for children who are unable to take oral medication and cannot rapidly reach a facility for parenteral treatment. We investigated factors influencing caretakers' adherence to referral advice following pre-referral treatment of their children with rectal artesunate suppositories.
METHODS: The study was nested within an intervention study that involved pre-referral treatment of all children who came to a community dispenser for treatment because they were unable to take oral medications because of repeated vomiting, lethargy, convulsions or altered consciousness. All patients who did not comply with referral advice were stratified by actions taken post-referral: taking their children to a drug shop, a traditional healer, or not seeking further treatment, and added to a random selection of patients who complied with referral advice. Caretakers of the children were interviewed about their socio-economic status (SES), knowledge about malaria, referral advice given and actions they took following pre-referral treatment. Interview data for 587 caretakers were matched with symptoms of the children, the time of treatment, arrival at a health facility or other actions taken post-pre-referral treatment.
RESULTS: The majority (93.5%) of caretakers reported being given referral advice by the community drug dispenser. The odds of adherence with this advice were three times greater for children with altered consciousness and/or convulsions than for children with other symptoms [odds ratio (OR) 3.47, 95% confidence interval (CI) 2.32-5.17, P < 0.001]. When questioned, caretakers who remembered when (OR 2.19, 95% CI 1.48-3.23, P < 0.001) and why (OR 1.77, 95% CI 1.07-2.95, P = 0.026) they were advised to proceed to health facility - were more likely to follow referral advice. Cost did not influence adherence except within a catchment area of facilities that charged for services. In these areas, costs deterred adherence by four to five times for those who had previously paid for laboratory services (OR = 0.25, 95% CI: 0.09-0.67, P = 0.006) or consultation (OR 0.20, 95% CI: 0.06-0.61, P = 0.005) compared with those who had not.
CONCLUSION: When given referral advice, caretakers of patients with life-threatening symptoms adhere to referral advice more readily than other caretakers. Health service charges deter adherence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497077     DOI: 10.1111/j.1365-3156.2009.02299.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  22 in total

1.  Knowledge and acceptability of the rectal treatment route in Laos and its application for pre-referral emergency malaria treatment.

Authors:  Southisouk Inthavilay; Thierry Franchard; Yang Meimei; Elizabeth A Ashley; Hubert Barennes
Journal:  Malar J       Date:  2010-11-27       Impact factor: 2.979

2.  Pediatric suppositories of sulpiride solid dispersion for treatment of Tourette syndrome: in vitro and in vivo investigations.

Authors:  Ahmed S Zidan; Sherif E Emam; Tamer M Shehata; Fakhr-eldin S Ghazy
Journal:  AAPS PharmSciTech       Date:  2014-12-11       Impact factor: 3.246

3.  Understanding caretakers' dilemma in deciding whether or not to adhere with referral advice after pre-referral treatment with rectal artesunate.

Authors:  Daudi O Simba; Deodatus C Kakoko; Marian Warsame; Zul Premji; Melba F Gomes; Goran Tomson; Eva Johansson
Journal:  Malar J       Date:  2010-05-12       Impact factor: 2.979

4.  Primacy of effective communication and its influence on adherence to artemether-lumefantrine treatment for children under five years of age: a qualitative study.

Authors:  Daudi O Simba; Deodatus Kakoko
Journal:  BMC Health Serv Res       Date:  2012-06-08       Impact factor: 2.655

5.  Low referral completion of rapid diagnostic test-negative patients in community-based treatment of malaria in Sierra Leone.

Authors:  Anna Thomson; Mohammed Khogali; Martin de Smet; Tony Reid; Ahmed Mukhtar; Stefan Peterson; Johan von Schreeb
Journal:  Malar J       Date:  2011-04-17       Impact factor: 2.979

6.  Pre-referral rectal artesunate in severe malaria: flawed trial.

Authors:  Karim F Hirji; Zulfiqarali G Premji
Journal:  Trials       Date:  2011-08-08       Impact factor: 2.279

Review 7.  Improving access to health care for malaria in Africa: a review of literature on what attracts patients.

Authors:  James Kizito; Miriam Kayendeke; Christine Nabirye; Sarah G Staedke; Clare I R Chandler
Journal:  Malar J       Date:  2012-02-23       Impact factor: 2.979

8.  Introducing the concept of a new pre-referral treatment for severely ill febrile children at community level: a sociological approach in Guinea-Bissau.

Authors:  Audrey Vermeersch; Anaëlle Libaud-Moal; Amabelia Rodrigues; Nicholas J White; Piero Olliaro; Melba Gomes; Elizabeth A Ashley; Pascal Millet
Journal:  Malar J       Date:  2014-02-06       Impact factor: 2.979

9.  High compliance with newborn community-to-facility referral in eastern Uganda:.an opportunity to improve newborn survival.

Authors:  Christine Kayemba Nalwadda; Peter Waiswa; Juliet Kiguli; Gertrude Namazzi; Sarah Namutamba; Göran Tomson; Stefan Peterson; David Guwatudde
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

10.  Pharmaceutical development and optimization of azithromycin suppository for paediatric use.

Authors:  Tina Kauss; Alexandra Gaubert; Chantal Boyer; Boubakar B Ba; Muriel Manse; Stephane Massip; Jean-Michel Léger; Fawaz Fawaz; Martine Lembege; Jean-Michel Boiron; Xavier Lafarge; Niklas Lindegardh; Nicholas J White; Piero Olliaro; Pascal Millet; Karen Gaudin
Journal:  Int J Pharm       Date:  2012-12-03       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.